Linzess vs Ibsrela
A side-by-side look at two gastrointestinal medications advertised on TV. Informational only — not medical advice.
| US Linzess | US Ibsrela | |
|---|---|---|
| Generic name | linaclotide | tenapanor |
| Drug class | Guanylate Cyclase-C Agonist | Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor |
| Treats | Irritable bowel syndrome with constipation, chronic constipation | Irritable bowel syndrome with constipation (IBS-C) |
| Category | Gastrointestinal | Gastrointestinal |
| Manufacturer | AbbVie/Ironwood | Ardelyx |
| Year approved | 2012 | 2019 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $140M | — |
| Common side effects | Diarrhea, Abdominal pain, Gas, Bloating | Diarrhea, Should not be used in young children (boxed warning), Gas, Abdominal pain |
Frequently asked questions
Is Linzess or Ibsrela better?
Neither is universally "better." Linzess (linaclotide) and Ibsrela (tenapanor) are both used for gastrointestinal, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Linzess and Ibsrela?
Linzess is a Guanylate Cyclase-C Agonist made by AbbVie/Ironwood, while Ibsrela is a Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor made by Ardelyx. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Linzess has the larger estimated TV advertising budget of the two.